NEW ORLEANS — A bunch of biotechs bravely made the journey to AACR22, seeking to acquire some favorable protection with the information drop on the Friday forward of the convention. However with one notable exception, the bears answerable for Wall Avenue sentiment blasted weak or merely encouraging knowledge, additional darkening an already ominous cloud lingering over the struggling biotech sector.
The roster of market losers was dominated by Rubius, with Zentalis, Genocea and C4 Therapeutics all getting beat up badly as nicely. Josh Schimmer at Evercore ISI counted eight small-to-mid cap firms placing up knowledge for AACR on Friday.
Preserve studying Endpoints with a free subscription
Unlock this story immediately and be part of 138,700+ biopharma execs studying Endpoints each day — and it is free.
